

Image

BOX SEQUENCE
1644



AS FILED Feb. 18, 2004

Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Comwell
Robert W. Esmond
Tracy-Gene G. Dunkin
Michele A. Cimbalia
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugalsky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Heidi L. Kraus
Edward W. Yee
Albert L. Ferro*
Donald R. Banowitz
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaston
Kimberly N. Reddick

Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhuillier
Rae Lynn Prengaman
Jane Shershenovich*
Lawrence J. Carroll*
George S. Bardmesser
Daniel A. Klein*
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller*
LuAnne M. Yuricek*
John J. Figueroa
Ann E. Summerfield
Tiera S. Coston*

Aric W. Ledford*
Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Helene C. Carlson
Gaby L. Longsworth
Matthew J. Dowd
Aaron L. Schwartz
Mary B. Tung
Katrina Y. Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Timothy A. Doyle
Jennifer R. Mahalingappa
Teresa A. Colella
Jeffrey S. Lundgren

Victoria S. Rutherford
Eric D. Hayes
Of Counsel
Kenneth C. Bass III
Evan R. Smith
*Admitted only in Maryland
*Admitted only in Virginia
•Practice Limited to
Federal Agencies

February 17, 2004

WRITER'S DIRECT NUMBER:
(202) 772-8641
INTERNET ADDRESS:
HCARLSON@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Re: U.S. Utility Patent Application
Application No. 09/458,302; Filed: December 10, 1999
For: **Inducing Cellular Immune Responses to Carcinoembryonic Antigen
Using Peptide and Nucleic Acid Compositions**
Inventors: FIKES *et al.*
Our Ref: 2060.0080005/HCC/PAC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Preliminary Amendment Under 37 C.F.R. § 1.115 and Submission Of Substitute Sequence Listing Under 37 C.F.R. § 1.825(a);
2. Paper copy of Substitute Sequence Listing (500 pages);
3. A computer readable copy of the Substitute Sequence Listing; and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
February 17, 2004
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Helene C. Carlson
Agent for Applicants
Registration No. 47,473

HCC/PAC/M-M/lvt
229827_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

FIKES *et al.*

Appl. No.: 09/458,302

Filed: December 10, 1999

For: **Inducing Cellular Immune
Responses to Carcinoembryonic
Antigen Using Peptide and Nucleic
Acid Compositions**

Confirmation No. 8701

Art Unit: 1644

Examiner: Schwadron, R.

Atty. Docket: 2060.0080005/HCC/PAC

**Preliminary Amendment Under 37 C.F.R. § 1.115 and Submission Of
Substitute Sequence Listing Under 37 C.F.R. § 1.825(a)**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In advance of prosecution, Applicants submit the following amendments and remarks. This Preliminary Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent

abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.